Daiichi Sankyo Company, Limited announced that it will launch Memary 5mg, 10mg and 20mg Tablets (generic name: memantine hydrochloride, Approval to Manufacture and Market: January 21) given once daily for the treatment of moderate to severe Alzheimer’s Disease on Wednesday, June 8.
The launch in Japan of Memary had previously been postponed on March 16 following the Tohoku Pacific Offshore Earthquake.
Date: April 27, 2011
Source: Daiichi Sankyo Company, Limited
